| Makale Türü |
|
||
| Dergi Adı | Obm Genetics | ||
| Dergi ISSN | 2577-5790 Scopus Dergi | ||
| Makale Dili | İngilizce | Basım Tarihi | 04-2024 |
| Cilt / Sayı / Sayfa | 8 / 1 / – | DOI | 10.21926/obm.genet.2401214 |
| Özet |
| As proof has recommended a close connection between COVID-19 and neurodegenerative disorders, this article aims to investigate the chloroquine (CLQ) drug as the SARS-CoV-2’s primary protease, which can prevent in vitro viral duplication of all diverse experiments to present. CLQ is an anti-viral drug enlarged by Pfizer, which can operate as an orally effective 3C-like protease inhibitor. In this study, CLQ has been assessed for its effectiveness against coronavirus by trapping it within a boron nitride nanocage (B |
| Anahtar Kelimeler |
| CLQ | COVID-19 | Drug delivery | Y–B4N10 (Y = Al, C, Si) |
| Atıf Sayıları | |
| Scopus | 3 |
| Dergi Adı | OBM Genetics |
| Yayıncı | LIDSEN Publishing Inc |
| Açık Erişim | Hayır |
| E-ISSN | 2577-5790 |
| CiteScore | 0,7 |
| SJR | 0,147 |
| SNIP | 0,167 |